We identified 12 patients with FUS-TFCP2 (n = 8) or EWSR1-TFCP2 (n = 4) in the prospective precision oncology programs MASTER22 (Molecularly Aided Stratification for Tumor Eradication Research; adults, n = 9) and INFORM23 (Individualized Therapy for Relapsed Malignancies in Childhood; children and adolescents, n = 3) (Supplementary Data 1). Here, FUS is linked to neoplasm.